See more : Nang Kuang Pharmaceutical Co., Ltd. (1752.TW) Income Statement Analysis – Financial Results
Complete financial analysis of CytoMed Therapeutics Limited (GDTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CytoMed Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sunset Island Group, Inc. (SIGO) Income Statement Analysis – Financial Results
- Heads UP Ventures Limited (HEADSUP.NS) Income Statement Analysis – Financial Results
- Gérard Perrier Industrie S.A. (PERR.PA) Income Statement Analysis – Financial Results
- Lepidico Limited (LPD.AX) Income Statement Analysis – Financial Results
- Matching Service Japan Co., Ltd. (6539.T) Income Statement Analysis – Financial Results
CytoMed Therapeutics Limited (GDTC)
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 290.56K | 270.34K | 84.18K | 44.92K | 0.00 |
| Cost of Revenue | 77.47K | 6.48K | 2.59K | 3.50K | 0.00 |
| Gross Profit | 213.09K | 263.86K | 81.59K | 41.43K | 0.00 |
| Gross Profit Ratio | 73.34% | 97.60% | 96.92% | 92.22% | 0.00% |
| Research & Development | 1.20M | 1.13M | 806.45K | 784.20K | 323.98K |
| General & Administrative | 344.25K | 443.29K | 433.47K | 112.32K | 0.00 |
| Selling & Marketing | 25.24K | 0.00 | 1.83K | 4.67K | 0.00 |
| SG&A | 1.93M | 443.29K | 435.31K | 116.99K | 29.72K |
| Other Expenses | 0.00 | -195.32K | 36.13K | 47.81K | 0.00 |
| Operating Expenses | 3.12M | 1.38M | 1.28M | 949.00K | 451.04K |
| Cost & Expenses | 3.20M | 1.38M | 1.28M | 949.00K | 451.04K |
| Interest Income | 38.73K | 1.56K | 2.49K | 79.71K | 20.06K |
| Interest Expense | 0.00 | 92.99K | 87.03K | 79.71K | 0.00 |
| Depreciation & Amortization | 77.47K | 291.84K | 243.92K | 220.99K | 97.23K |
| EBITDA | -2.94M | -1.11M | -1.19M | -728.02K | -349.62K |
| EBITDA Ratio | -1,011.10% | -410.85% | -1,412.07% | -1,620.57% | 0.00% |
| Operating Income | -2.91M | -1.40M | -1.43M | -949.00K | -446.85K |
| Operating Income Ratio | -1,002.20% | -518.81% | -1,701.84% | -2,112.48% | 0.00% |
| Total Other Income/Expenses | -219.50K | -922.48K | -320.96K | -513.22K | -19.10K |
| Income Before Tax | -3.13M | -2.33M | -1.53M | -1.47M | -465.95K |
| Income Before Tax Ratio | -1,077.75% | -860.05% | -1,822.31% | -3,266.03% | 0.00% |
| Income Tax Expense | 373.69 | 1.22K | -53.43K | 84.71K | 0.00 |
| Net Income | -3.13M | -2.40M | -1.53M | -1.47M | -465.95K |
| Net Income Ratio | -1,077.85% | -887.02% | -1,822.31% | -3,266.03% | 0.00% |
| EPS | -0.29 | -0.30 | -0.22 | -0.25 | -0.08 |
| EPS Diluted | -0.29 | -0.30 | -0.22 | -0.25 | -0.08 |
| Weighted Avg Shares Out | 10.63M | 7.92M | 6.93M | 5.90M | 5.55M |
| Weighted Avg Shares Out (Dil) | 10.63M | 7.92M | 6.93M | 5.90M | 5.55M |
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT)...
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for treating a range of cancers,...
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and...
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related...
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a Malaysia, US and China patent The Company now has exclusive rights to a Malaysia, US and China patent
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
SINGAPORE , Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced...
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE , Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived...
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will...
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently...
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
SINGAPORE , Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that...
Source: https://incomestatements.info
Category: Stock Reports